Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)
NCT01704716Phase 3Recruiting
- Sponsor
- St. Anna Children's Cancer Research Institute
- Start
- Feb 2002
- Primary completion
- Sep 2021
- Modality
- Antibody Conjugates, DNA Intercalators/Alkylators, Classical Binding Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of Dinutuximab beta, aldesleukin, busulfan, melphalan, carboplatin in neuroblastoma, sponsored by St. Anna Children's Cancer Research Institute. Started Feb 2002; status: recruiting.
02
Drugs
Dinutuximab betaaldesleukinbusulfanmelphalancarboplatin
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT01704716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01704716.